Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2016 Financial Results
Conference Call to be Held Today at 4:30 P.M. ET
View HTML
Toggle Summary Aviragen Therapeutics Announces Rescheduled Date and Time of Fourth Quarter and Fiscal Year 2016 Financial Results on September 14, 2016
ATLANTA , Sept. 13, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Wednesday, September 14, 2016
View HTML
Toggle Summary Aviragen Therapeutics to Present at Upcoming Investor Conferences
ATLANTA , Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, announced today that Aviragen's CEO & President Joseph Patti, PhD will present a corporate
View HTML
Toggle Summary Aviragen Therapeutics Announces Inducement Grant for New Employees
ATLANTA , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, announced today that the Company has granted two new hires options to purchase an aggregate
View HTML
Toggle Summary Aviragen Therapeutics Announces Schedule Change for Fourth Quarter and Fiscal Year End 2016 Financial Results Conference Call and Webcast
ATLANTA , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, announced today that it is delaying the time of its fourth quarter and fiscal year end 2016
View HTML
Toggle Summary Aviragen Therapeutics to Host Conference Call to Report Fourth Quarter and Fiscal Year 2016 Financial Results on September 8, 2016
ATLANTA , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, September 8, 2016
View HTML
Toggle Summary Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial
ATLANTA , July 12, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, today announced it is resuming enrollment in its Phase 2a challenge study of BTA585, an oral
View HTML
Toggle Summary Aviragen Therapeutics and Georgia State University Research Foundation Enter Exclusive License and Sponsored Research Agreement to Develop Novel Antiviral Therapies
ATLANTA , July 05, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has entered into an exclusive, worldwide license and sponsored
View HTML
Toggle Summary Aviragen Therapeutics Announces Inducement Grant for New Employee
ATLANTA , July 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, announced today that the compensation committee of the Company's Board of Directors granted
View HTML
Toggle Summary Aviragen Therapeutics Announces the Appointment of Jonas Niaura as Vice President, Corporate Development and Strategy
ATLANTA , June 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced the appointment of Jonas Niaura as Vice President, Corporate Development and Strategy.
View HTML
Toggle Summary Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections
ATLANTA , May 26, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily decided to delay further enrollment in the Phase 2a
View HTML
Toggle Summary Aviragen Therapeutics Reports Third Quarter Fiscal Year 2016 Financial Results
Conference Call to be Held Today at 4:30 P.M. ET
View HTML
Toggle Summary Aviragen Therapeutics to Host Conference Call to Report Third Quarter Fiscal Year 2016 Financial Results on May 5, 2016
ATLANTA , April 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ) a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, May 5, 2016 at 4:30
View HTML
Toggle Summary Aviragen Therapeutics Completes Royalty Deal With HealthCare Royalty Partners for Proceeds of $20 Million
Non-Dilutive Financing Provides for Company's Continued Participation in Future Royalties
View HTML
Toggle Summary Aviragen Therapeutics to Participate in FBR & Co. Healthcare Series Focused on Infectious Diseases
ATLANTA , April 14, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. , (NASDAQ:AVIR), formerly Biota Pharmaceuticals, Inc., today announced that Joseph Patti , PhD, President & CEO of Aviragen Therapeutics , will participate in a panel discussion titled, "Notable Emerging Anti-Viral Agents" as
View HTML

Log In

Create an account